Found in the ISIS website...Drugs in Development.
ATL1102
ATL1102 is an antisense inhibitor of CD49d, which is a subunit of Very Late Antigen-4, or VLA-4. Studies in animal models have demonstrated that inhibiting VLA-4 positively affects a number of inflammatory diseases, including multiple sclerosis, or MS.
We licensed ATL1102 to Antisense Therapeutics Limited in December 2001. In 2008, ATL reported Phase 2a results of ATL1102 showing significantly reduced disease activity in patients with relapsing remitting MS.
antisense pharma...connection?, page-40
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.0¢ |
Change
-0.001(1.23%) |
Mkt cap ! $82.94M | |||
| Open | High | Low | Value | Volume |
| 8.0¢ | 8.0¢ | 7.9¢ | $184.6K | 2.329M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 300000 | 7.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.0¢ | 451116 | 7 |
View Market Depth
| Last trade - 14.44pm 01/11/2024 (20 minute delay) ? |
| PER (ASX) Chart |